Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from PCSA

Pat Forde: Protect College Sports Act’s New Expansion Provision Could Put ACC on Chopping Block

The latest version of the PCSA would open the door to further Power 2 expansion as media rights begin to expire.

Sports Illustrated

Pat Forde: Congress Is Coming for the SEC and Big Ten’s College Sports Empire

The Protect College Sports Act reflects mounting frustration with the Power 2’s dominance and could force them to consider drastic next steps.

Sports Illustrated

The Brendan Sorsby Saga Collides With Congress in a Defining Week for College Sports

As Big 12 leaders weigh potential sanctions against Texas Tech, lawmakers in Washington are debating legislation that could reshape the NCAA's power.

Sports Illustrated

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Processa Pharmaceuticals Stock Rose Almost 38% Overnight?

Processa Pharmaceuticals Inc. (NASDAQ:PCSA) shares soared 37.5% to $0.50 during after-hours trading on Tuesday.

Benzinga

Why Insiders Are Aggressively Buying This Under $1 Stock

While insiders are showing significant interest in penny stock Processa Pharmaceuticals (PCSA), the stock has witnessed a weak momentum over the past year. Let’s take a look at its key metrics to understand if there is any hope for sustainable share price appreciation. Read on.

StockNews.com

Preview: Processa Pharmaceuticals's Earnings

Processa Pharmaceuticals (NASDAQ:PCSA) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that Processa Pharmaceuticals will report an earnings per share (EPS) of $-0.21.

Benzinga

Processa Pharmaceuticals Earnings Preview

Processa Pharmaceuticals (NASDAQ:PCSA) is set to give its latest quarterly earnings report on Wednesday, 2022-03-30. Here's what investors need to know before the announcement. Analysts estimate that Processa Pharmaceuticals will report an earnings per share (EPS) of $-0.19.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.